

Michael J Rybak

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/10691076/michael-j-rybak-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

218
papers

16,724
citations

65
h-index

124
g-index

221
ext. papers

19,139
ext. citations

6.1
avg. IF

6.64
L-index

#	Paper	IF	Citations
218	Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Bloodstream Infection.. <i>Open Forum Infectious Diseases</i> , 2022 , 9, ofab606	1	1
217	Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant. <i>Pharmaceutics</i> , 2021 , 13,	6.4	3
216	Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. <i>Clinical Infectious Diseases</i> , 2021 , 73, e4560-e4567	11.6	4
215	Validity of 2020 vancomycin consensus recommendations and further guidance for practical application. <i>American Journal of Health-System Pharmacy</i> , 2021 , 78, 1364-1367	2.2	1
214	Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Bacteremia: STAPH Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab261	1	2
213	Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of in a Pharmacokinetic/Pharmacodynamic Model. <i>Antibiotics</i> , 2020 , 9,	4.9	7
212	Combination of Vancomycin or Daptomycin and Beta-lactam Antibiotics: A Meta-analysis. <i>Pharmacotherapy</i> , 2020 , 40, 648-658	5.8	11
211	A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2020 , 39, 2199-2203	5.3	4
210	Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	9
209	Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β -Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium. <i>Journal of Infectious Diseases</i> , 2020 , 222, 1531-1539	7	2
208	Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of Health-System Pharmacy</i> ,	2.2	307
207	A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 89-106	6.2	11
206	Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β -Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 325-339	6.2	13
205	Multicenter Cohort of Patients With Methicillin-Resistant Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofz538	1	30
204	Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1211-1214	11.6	55
203	The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy. <i>Antibiotics</i> , 2020 , 9,	4.9	8
202	Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	5

201	Daptomycin Plus β -Lactam Combination Therapy for Methicillin-resistant Staphylococcus aureus Bloodstream Infections: A Retrospective, Comparative Cohort Study. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1-10	11.6	39
200	Impact of Daptomycin Dose Exposure Alone or in Combination with β -Lactams or Rifampin against Vancomycin-Resistant Enterococci in an Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	6
199	Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of in a Simulated Pharmacodynamic/Pharmacokinetic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	14
198	Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	12
197	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz077	1	6
196	Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients. <i>Journal of Global Antimicrobial Resistance</i> , 2019 , 17, 16-18	3.4	2
195	Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 199-208	6.2	5
194	Reply to Koehler et al. <i>Clinical Infectious Diseases</i> , 2019 , 69, 901-902	11.6	1
193	The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Bloodstream Infections Treated With Vancomycin. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz079	1	8
192	Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis in an Simulated Endocarditis Vegetation Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	5
191	A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 843-850	5.3	2
190	Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. <i>International Journal of Antimicrobial Agents</i> , 2019 , 54, 346-350	14.3	5
189	Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 627-640	6.2	6
188	Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 229-242	6.2	3
187	Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1650-1657	11.6	22
186	Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 489-498	5.1	21
185	Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study. <i>Infectious Diseases and Therapy</i> , 2019 , 8, 75-85	6.2	1
184	Evaluation of dalbavancin alone and in combination with β -lactam antibiotics against resistant phenotypes of Staphylococcus aureus. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 82-86	5.1	10

183	Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 161-169	6.2	6
182	A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2018 , 67, 303-309	11.6	92
181	β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	30
180	Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in a Model of Simulated Endocardial Vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	11
179	Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	72
178	Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting. <i>Infectious Diseases and Therapy</i> , 2018 , 7, 495-507	6.2	2
177	Making the change to area under the curve-based vancomycin dosing. <i>American Journal of Health-System Pharmacy</i> , 2018 , 75, 1986-1995	2.2	53
176	Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	16
175	Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in a Biofilm Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	5
174	Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 91, 363-370	2.9	10
173	Role of Combination Antimicrobial Therapy for Vancomycin-Resistant Enterococcus faecium Infections: Review of the Current Evidence. <i>Pharmacotherapy</i> , 2017 , 37, 579-592	5.8	50
172	Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs). <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 2290-2296	5.1	13
171	Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	41
170	Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients. <i>Diagnostic Microbiology and Infectious Disease</i> , 2017 , 87, 338-342	2.9	6
169	A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	126
168	β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	7
167	Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime. <i>Clinical Infectious Diseases</i> , 2017 , 64, 116-123	11.6	114
166	Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	12

165 Daptomycin Resistance **2017**, 307-317

164	Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> and Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Infectious Diseases and Therapy</i> , 2016 , 5, 367-77	6.2	7
163	Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant <i>Staphylococcus aureus</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5841-8	5.9	38
162	Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 5716-23	5.9	27
161	Oritavancin Combinations with β -Lactams against Multidrug-Resistant <i>Staphylococcus aureus</i> and Vancomycin-Resistant Enterococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 2352-8	5.9	19
160	Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion?. <i>American Journal of Infection Control</i> , 2016 , 44, 47-9	3.8	3
159	Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. <i>Clinical Infectious Diseases</i> , 2016 , 62, 1242-1250	11.6	64
158	Pneumonia Caused by Methicillin-Resistant <i>Staphylococcus aureus</i> : Does Vancomycin Heteroresistance Matter?. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 1708-16	5.9	24
157	Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3743-50	5.9	47
156	Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible <i>Staphylococcus aureus</i> in an In Vitro, Hollow-Fiber Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3970-5	5.9	14
155	β -Lactam combinations with daptomycin provide synergy against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1738-43	5.1	75
154	Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant <i>Staphylococcus aureus</i> infective endocarditis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2978-85	5.9	47
153	Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant <i>Staphylococcus aureus</i> infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 1969-76	5.9	27
152	β -Lactams enhance daptomycin activity against vancomycin-resistant <i>Enterococcus faecalis</i> and <i>Enterococcus faecium</i> in in vitro pharmacokinetic/pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 2842-8	5.9	32
151	Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. <i>Circulation</i> , 2015 , 132, 1435-86	16.7	1479
150	Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 311-3	5.1	34
149	The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 505-9	5.1	30
148	Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in <i>Staphylococcus aureus</i> : Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 60, 1584-91	5.9	16

147	Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury. <i>Infectious Diseases and Therapy</i> , 2015 , 4, 519-28	6.2	8
146	Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. <i>Pharmacotherapy</i> , 2015 , 35, 935-48	5.8	33
145	Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 4497-503	5.9	29
144	Nephrotoxicity comparison of two commercially available generic vancomycin products. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5470-4	5.9	15
143	Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. <i>Journal of Emergency Medicine</i> , 2015 , 48, 508-19	1.5	72
142	Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 1272-3	5.1	1
141	Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm. <i>Infectious Diseases and Therapy</i> , 2014 , 4, 51	6.2	55
140	Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. <i>Clinical Therapeutics</i> , 2014 , 36, 1317-33	3.5	118
139	Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3006-10	5.1	36
138	High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. <i>Current Infectious Disease Reports</i> , 2014 , 16, 429	3.9	20
137	Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 3177-81	5.9	35
136	Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2541-6	5.9	84
135	Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4636-41	5.9	11
134	A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 2989-92	5.9	29
133	Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2148-54	5.1	45
132	Daptomycin: Pharmacokinetic, Pharmacodynamic, and Dose Optimization 2014 , 381-399		
131	Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains. <i>Infectious Diseases and Therapy</i> , 2014 , 3, 35-43	6.2	52
130	Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: a cross-sectional survey of U.S. hospitals. <i>Pharmacotherapy</i> , 2013 , 33, 1256-63	5.8	47

129	Reduced glycopeptide and lipopeptide susceptibility in <i>Staphylococcus aureus</i> and the "seesaw effect": Taking advantage of the back door left open?. <i>Drug Resistance Updates</i> , 2013 , 16, 73-9	23.2	43
128	Evaluation of Daptomycin Non-Susceptible <i>Staphylococcus aureus</i> for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity. <i>Infectious Diseases and Therapy</i> , 2013 , 2, 187-200	6.2	7
127	Current and prospective treatments for multidrug-resistant gram-positive infections. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1919-32	4	35
126	Early use of daptomycin versus vancomycin for methicillin-resistant <i>Staphylococcus aureus</i> bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1562-9	11.6	134
125	Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant <i>Staphylococcus aureus</i> bacteremia. <i>Pharmacotherapy</i> , 2013 , 33, 3-10	5.8	30
124	Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. <i>International Journal of Antimicrobial Agents</i> , 2013 , 42, 202-10	14.3	71
123	Comparative epidemiology of bacteremia due to methicillin-resistant <i>Staphylococcus aureus</i> between older and younger adults: a propensity score analysis. <i>Infection Control and Hospital Epidemiology</i> , 2013 , 34, 400-6	2	7
122	Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Infectious Diseases</i> , 2013 , 208, 67-74	7	35
121	Multicenter study of high-dose daptomycin for treatment of enterococcal infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4190-6	5.9	72
120	Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate <i>Staphylococcus aureus</i> Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 4252-4259	5.9	58
119	A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 2921-6	5.1	75
118	Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate <i>Staphylococcus aureus</i> in a pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 66-73	5.9	98
117	Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate <i>Staphylococcus aureus</i> and vancomycin-intermediate methicillin-resistant <i>S. aureus</i> strains in an in vitro pharmacokinetic/pharmacodynamic model: exploring the "seesaw effect". <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2664-8	5.9	48
116	Evaluation of vancomycin susceptibility testing for methicillin-resistant <i>Staphylococcus aureus</i> : comparison of Etest and three automated testing methods. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2077-81	9.7	58
115	Treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections with a minimal inhibitory concentration of 2 µg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1587-97	2.9	34
114	Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. <i>Pharmacotherapy</i> , 2012 , 32, 195-201	5.8	68
113	Evaluation of telavancin activity versus daptomycin and vancomycin against daptomycin-nonsusceptible <i>Staphylococcus aureus</i> in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 955-9	5.9	19
112	Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant <i>Staphylococcus aureus</i> using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5700-14	5.9	28

111	Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 5990-3	5.9	26
110	Evaluation of standard- and high-dose daptomycin versus linezolid against vancomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 3174-80	5.9	76
109	In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. <i>International Journal of Antimicrobial Agents</i> , 2011 , 38, 301-6	14.3	9
108	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. <i>Clinical Infectious Diseases</i> , 2011 , 52, e18-55	11.6	1736
107	High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study. <i>Pharmacotherapy</i> , 2011 , 31, 527-36	5.8	112
106	Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3505-9	5.9	50
105	Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. <i>Clinical Infectious Diseases</i> , 2011 , 52, 975-81	11.6	356
104	Growing prevalence of vancomycin-resistant Enterococcus faecalis in the region with the highest prevalence of vancomycin-resistant Staphylococcus aureus. <i>Infection Control and Hospital Epidemiology</i> , 2011 , 32, 922-4	2	20
103	Evaluation of ceftaroline activity versus daptomycin (DAP) against DAP-nonsusceptible methicillin-resistant Staphylococcus aureus strains in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 3522-6	5.9	32
102	Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. <i>Clinical Infectious Diseases</i> , 2011 , 52, 285-92	11.6	1209
101	Reply to Cataldo et al. <i>Clinical Infectious Diseases</i> , 2011 , 53, 310-310	11.6	
100	Impact of dose de-escalation and escalation on daptomycin pharmacodynamics against clinical methicillin-resistant Staphylococcus aureus isolates in an in vitro model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2160-5	5.9	12
99	Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 4748-54	5.9	17
98	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4329-34	5.9	95
97	Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5187-92	5.9	50
96	Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated methicillin-resistant Staphylococcus aureus. <i>International Journal of Antimicrobial Agents</i> , 2010 , 35, 25-9	14.3	12
95	In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired methicillin-resistant Staphylococcus aureus (HA-MRSA) isolates. <i>International Journal of Antimicrobial Agents</i> , 2010 , 35, 527-30	14.3	21
94	Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2009 , 49, 325-7	11.6	566

93	Activity of telavancin against <i>Staphylococcus aureus</i> strains with various vancomycin susceptibilities in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2928-33	5.9	22
92	In vitro activity of ceftaroline against methicillin-resistant <i>Staphylococcus aureus</i> and heterogeneous vancomycin-intermediate <i>S. aureus</i> in a hollow fiber model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4712-7	5.9	69
91	Evaluation of the Etest GRD for the detection of <i>Staphylococcus aureus</i> with reduced susceptibility to glycopeptides. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 489-92	5.1	59
90	Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant <i>Staphylococcus aureus</i> isolates collected in nine U.S. medical centers from 2002 to 2006. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 4127-32	5.9	108
89	Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among <i>Staphylococcus aureus</i> causing bloodstream infections in nine USA hospitals. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 1024-8	5.1	50
88	Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant <i>Staphylococcus aureus</i> isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. <i>Journal of Infectious Diseases</i> , 2009 , 199, 1558-9	7	107
87	Impact of inoculum size and heterogeneous vancomycin-intermediate <i>Staphylococcus aureus</i> (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 805-7	5.9	28
86	Accessory gene regulator dysfunction: an advantage for <i>Staphylococcus aureus</i> in health-care settings?. <i>Journal of Infectious Diseases</i> , 2009 , 199, 1558-9	7	20
85	Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2009 , 29, 1275-9	5.8	207
84	Evaluation of vancomycin and daptomycin against methicillin-resistant <i>Staphylococcus aureus</i> and heterogeneously vancomycin-intermediate <i>S. aureus</i> in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 155-60	5.1	23
83	Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. <i>Pharmacotherapy</i> , 2008 , 28, 458-68	5.8	37
82	Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008 , 60, 441-4	2.9	29
81	Ceragenins: cholic acid-based mimics of antimicrobial peptides. <i>Accounts of Chemical Research</i> , 2008 , 41, 1233-40	24.3	138
80	Characterization of vancomycin-heteroresistant <i>Staphylococcus aureus</i> from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2958-74	5.4	120
79	daptomycin activity against <i>Staphylococcus aureus</i> following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 831-6	5.9	70
78	Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against <i>Staphylococcus aureus</i> isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3061-7	5.9	78
77	Associations between the genotypes of <i>Staphylococcus aureus</i> bloodstream isolates and clinical characteristics and outcomes of bacteremic patients. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2890-6	9.7	64
76	Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant <i>Staphylococcus aureus</i> with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 2156-62	5.9	77

75	Clinical rationale for treatment of endocarditis caused by methicillin-susceptible <i>Staphylococcus aureus</i> developing nonsusceptibility to daptomycin. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 2471; author reply 2471-2	9.7	3
74	Evaluation of endocarditis caused by methicillin-susceptible <i>Staphylococcus aureus</i> developing nonsusceptibility to daptomycin. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 220-4	9.7	41
73	Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1305-10	5.1	17
72	Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of <i>Pseudomonas aeruginosa</i> , including multidrug-resistant <i>P. aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 61, 365-70	5.1	65
71	Antimicrobial susceptibility and staphylococcal chromosomal cassette mec type in community- and hospital-associated methicillin-resistant <i>Staphylococcus aureus</i> . <i>Pharmacotherapy</i> , 2007 , 27, 3-10	5.8	23
70	Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes. <i>Pharmacotherapy</i> , 2007 , 27, 1611-8	5.8	63
69	Antimicrobial activities of ceragenins against clinical isolates of resistant <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1268-73	5.9	89
68	Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1089-91	5.9	76
67	Fluoroquinolone resistance in <i>Streptococcus pneumoniae</i> : area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1315-20	5.9	26
66	Correlation of vancomycin and daptomycin susceptibility in <i>Staphylococcus aureus</i> in reference to accessory gene regulator (agr) polymorphism and function. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 1190-3	5.1	27
65	Evaluation of daptomycin treatment of <i>Staphylococcus aureus</i> bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 60, 334-40	5.1	66
64	Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3731-3	5.9	83
63	Community- and health care-associated methicillin-resistant <i>Staphylococcus aureus</i> : a comparison of molecular epidemiology and antimicrobial activities of various agents. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 58, 41-7	2.9	86
62	Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant <i>Staphylococcus aureus</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 338-43	5.1	115
61	Evaluation of daptomycin activity against <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model under normal and simulated impaired renal function. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 57, 116-21	5.1	25
60	Impact of <i>Enterococcus faecalis</i> on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant <i>Staphylococcus aureus</i> in a mixed-pathogen pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 1298-303	5.9	14
59	The pharmacokinetic and pharmacodynamic properties of vancomycin. <i>Clinical Infectious Diseases</i> , 2006 , 42 Suppl 1, S35-9	11.6	483
58	Characteristics of patients with healthcare-associated infection due to SCCmec type IV methicillin-resistant <i>Staphylococcus aureus</i> . <i>Infection Control and Hospital Epidemiology</i> , 2006 , 27, 1025-31		92

57	Pharmacodynamics: relation to antimicrobial resistance. <i>American Journal of Medicine</i> , 2006 , 119, S37-44; discussion S62-70	2.4	53
56	Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria. <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 54, 305-10	2.9	9
55	Clinical isolates of <i>Staphylococcus aureus</i> from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 51, 119-25	2.9	19
54	Epidemiology, treatment, and outcomes of nosocomial bacteremic <i>Staphylococcus aureus</i> pneumonia. <i>Chest</i> , 2005 , 128, 1414-22	5.3	91
53	Community-associated methicillin-resistant <i>Staphylococcus aureus</i> : a review. <i>Pharmacotherapy</i> , 2005 , 25, 74-85	5.8	89
52	Short-course gentamicin in combination with daptomycin or vancomycin against <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 2735-45	5.9	96
51	Pharmacodynamics of cefepime alone and in combination with various antimicrobials against methicillin-resistant <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 302-8	5.9	29
50	Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 259-62	5.1	38
49	Impact of high-inoculum <i>Staphylococcus aureus</i> on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4665-72	5.9	240
48	In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant <i>Staphylococcus aureus</i> and glycopeptide-intermediate susceptible staphylococci. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 2719-23	5.9	11
47	Daptomycin - a novel antibiotic against Gram-positive pathogens. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 2321-31	4	55
46	Daptomycin. <i>Pharmacotherapy</i> , 2004 , 24, 41-57	5.8	78
45	Resistance to antimicrobial agents: an update. <i>Pharmacotherapy</i> , 2004 , 24, 203S-15S	5.8	32
44	The importance of bactericidal drugs: future directions in infectious disease. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1314-20	11.6	153
43	In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against <i>Staphylococcus aureus</i> in a pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 150-60	14.3	38
42	Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. <i>Diagnostic Microbiology and Infectious Disease</i> , 2004 , 50, 125-30	2.9	33
41	Influences of linezolid, penicillin, and clindamycin, alone and in combination, on streptococcal pyrogenic exotoxin a release. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1752-5	5.9	70
40	Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003 , 13, 2109-12	2.9	69

39	Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of <i>Staphylococcus aureus</i> . <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003 , 13, 1745-9	2.9	48
38	Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant <i>Staphylococcus aureus</i> in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 3960-3	5.9	65
37	Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Diagnostic Microbiology and Infectious Disease</i> , 2003 , 47, 539-46	2.9	49
36	Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. <i>Surgical Infections</i> , 2003 , 4, 57-70	2	64
35	Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1853-61	5.9	90
34	Outcomes analysis of delayed antibiotic treatment for hospital-acquired <i>Staphylococcus aureus</i> bacteremia. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1418-23	11.6	474
33	Daptomycin dose-effect relationship against resistant gram-positive organisms. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1598-603	5.9	87
32	Linezolid and vancomycin, alone and in combination with rifampin, compared with moxifloxacin against a multidrug-resistant and a vancomycin-tolerant <i>Streptococcus pneumoniae</i> strain in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 1984-7	5.9	10
31	Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against <i>Streptococcus pneumoniae</i> in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2003 , 47, 2606-14	5.9	51
30	In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 2606-12	5.9	65
29	Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. <i>Clinical Infectious Diseases</i> , 2002 , 34, 922-9	11.6	117
28	Pharmacodynamics of cefepime in patients with Gram-negative infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 425-8	5.1	180
27	Comparison of length of hospital stay for patients with known or suspected methicillin-resistant <i>Staphylococcus</i> species infections treated with linezolid or vancomycin: a randomized, multicenter trial. <i>Pharmacotherapy</i> , 2001 , 21, 263-74	5.8	102
26	Activities of newer fluoroquinolones against ciprofloxacin-resistant <i>Streptococcus pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1654-9	5.9	39
25	Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant <i>Staphylococcus aureus</i> , vancomycin-resistant <i>Enterococcus faecium</i> , and methicillin-resistant <i>Staphylococcus aureus</i> isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 454-9	5.9	166
24	Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria. <i>Expert Opinion on Emerging Drugs</i> , 2001 , 6, 43-55		5
23	Emergence of methicillin-resistant <i>Staphylococcus aureus</i> with intermediate glycopeptide resistance: clinical significance and treatment options. <i>Drugs</i> , 2001 , 61, 1-7	12.1	85
22	Therapeutic options for Gram-positive infections. <i>Journal of Hospital Infection</i> , 2001 , 49 Suppl A, S25-32	6.9	8

21	Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: case report and review. <i>Pharmacotherapy</i> , 2000 , 20, 1116-9	5.8	14
20	Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function. <i>Pharmacotherapy</i> , 2000 , 20, 554-61	5.8	4
19	In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1925-9	5.9	64
18	Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1921-4	5.9	32
17	In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains. <i>Antimicrobial Agents and Chemotherapy</i> , 2000 , 44, 1062-6	5.9	275
16	Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 1914-8	5.9	40
15	Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 1549-55	5.9	324
14	Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of Staphylococcus aureus. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 335-40	5.9	101
13	Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 717-21	5.9	50
12	The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 343-9	5.1	30
11	Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. <i>Pharmacotherapy</i> , 1999 , 19, 1252-60	5.8	79
10	Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. <i>Pharmacotherapy</i> , 1999 , 19, 257-66	5.8	63
9	Treatment of vancomycin-resistant Enterococcus faecium with RP 59500 (quinupristin-dalfopristin) administered by intermittent or continuous infusion, alone or in combination with doxycycline, in an in vitro pharmacodynamic infection model with simulated endocardial vegetations. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 2710-7	5.9	40
8	Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperzolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. <i>Antimicrobial Agents and Chemotherapy</i> , 1999 , 43, 721-4	5.9	118
7	Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. <i>Drugs</i> , 1996 , 52, 390-405	12.1	82
6	Quinupristin/dalfopristin (RP 59500): a new streptogramin antibiotic. <i>Annals of Pharmacotherapy</i> , 1995 , 29, 1022-7	2.9	48
5	Ofloxacin clinical pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 1992 , 22, 32-46	6.2	31
4	Nephrotoxicity of vancomycin, alone and with an aminoglycoside. <i>Journal of Antimicrobial Chemotherapy</i> , 1990 , 25, 679-87	5.1	317

- 3 Inhibition of drug metabolism by quinolone antibiotics. *Clinical Pharmacokinetics*, **1988**, 15, 194-204 6.2 62
- 2 Increased theophylline concentrations secondary to ciprofloxacin. *Drug Intelligence & Clinical Pharmacy*, **1987**, 21, 879-81 25
- 1 Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. *Journal of Antimicrobial Chemotherapy*, **1986**, 17, 115-20 5.1 18